You are here: Home » Companies
;
Business Standard

Troubles behind it, Cadila surges aheadlkjlkjkjlkjj

Cadila hopes to double its revenue from the US in three years

Sohini Das  |  Ahmedabad 

This is article Banner

The shares of pharma major Cadila Healthcare, also known as Zydus Cadila, have been on a roll for the past few weeks. The stock's value rose almost 55 per cent to a six-month high of Rs 548.35 on June 12.

Cadila has edged past Lupin to become the second-most valuable pharmaceutical company by market capitalisation at Rs 54,719 crore. There were two triggers behind this sharp rise; one, the US Food and Drug Administration’s approval for the generic version of an ulcerative colitis drug Lialda (which has sales of $ 1.14 billion in the US); and two, the expectation of FDA ...

First Published: Wed, June 28 2017. 23:18 IST
RECOMMENDED FOR YOU


Notice: Undefined property: stdClass::$canonicalUrl in /usr2/unibs/application/modules/article/controllers/ManagerController.php on line 449